Interactive modules by Olga Goodman, MD.Copyright protected · Read termsClose terms

All RheumaView™ interactive modules, quizzes and educational cases are original works developed by Olga Goodman, MD.

Without the author’s prior written permission, you may not copy or republish these modules or their components; extract, reuse or modify their original software code (“engines”); or use that code to build your own modules, quizzes or other products.

You may not claim these works as your own or remove or replace the author’s name or copyright notices. When quoting material, credit Olga Goodman, MD, identify the source and include a direct link to the original.

Free or public access is provided for learning and does not grant permission to copy, adapt or redistribute the materials. Unauthorized use of protected material may constitute copyright infringement. Exceptions and limitations provided by applicable law remain unaffected.

Sharing direct links to the modules is welcome.

© 2026 Olga Goodman, MD. All rights reserved.

OSTEOARTHRITIS · CHAPTER 11

Osteoarthritis Treatment: What Fits Your Joint and Your Life?

Understand the evidence, compare realistic options and prepare the next decision.

Olga Goodman, MD
Rheumatology in Perspective · by Olga Goodman, MD · A RheumaView publication
Evidence reviewed: September 28, 2026

My decision sheet
On this page

1. There is no single treatment ladder for every joint

Start with three questions: which joint, which problem, and what do you want to do more comfortably? Opening a jar, walking to a shop and sleeping with less shoulder pain are different treatment goals.

This guide helps you understand a proposed treatment. It does not decide which medicine you should start. Recommendations for a knee cannot automatically be applied to the thumb, ankle or spine. Even a useful treatment may not suit your other health conditions. The major guidelines address different joints and patient groups. [2, 3, 4, 5]

2. When choosing a treatment is not the first task

A joint that becomes hot, very swollen and severely painful needs prompt assessment. Infection can occur without fever, and crystals do not rule it out. Do not simply arrange another routine injection. [23]

New difficulty emptying the bladder, numbness around the saddle area or rapidly worsening weakness with back symptoms needs immediate medical assessment. Sudden inability to use a limb after injury also needs a new assessment, not a harder exercise program. [24]

Black stools, vomiting blood, trouble breathing or severe medicine reactions require urgent help. These are not signs to wait until a scheduled OA review. [26]

3. What evidence labels actually mean

What you read What it means in everyday language
Supported treatment Research or a guideline supports a particular use—not guaranteed relief for everyone.
Conditional or selected option It may be reasonable for some people; your situation and preferences matter.
Uncertain or disputed We do not have a settled answer, or professional groups interpret the evidence differently. This is not proof that it works.
Not recommended for OA The expected balance is unfavorable in that setting. It does not automatically mean stopping the same medicine for another disease.
Research result A possibility has been studied; that is different from an established, approved treatment.

These are explanations, not a score for choosing your treatment. A strong recommendation does not necessarily mean a large benefit, and an uncertain result is not a promise waiting to be purchased. [2, 3, 22]

4. Useful care is more than a prescription

A practical plan may include movement, muscle work, pacing tasks, adapted tools, an appropriate support and medicines when suitable. The aim is to help you do something that matters, not merely to collect a longer list of treatments. Hand and hip/knee guidelines emphasize these practical components. [3, 4, 5]

Choose one activity as a starting point. Record what limits it now, what change is being tried and when to review the result. A walking aid that is difficult to grip or an insert that creates pressure needs adjustment; buying it is not the same as benefiting from it.

Treatment can improve one thing without improving everything. Less pain but continued difficulty dressing deserves a closer look at the remaining limitation. Better walking without a lower pain number may still matter if it is safe and acceptable.

5. Hands: the painful joint and the type of OA matter

A support for the thumb base does not have the same job as treatment of a swollen finger joint. Task changes, hand exercises, selected supports and local pain treatment are part of hand-OA care. [5, 10]

Erosive hand OA has its own discussion. The ACR’s 2026 guidance allows methotrexate as a conditional option, with considerable uncertainty. A relevant trial studied people with hand OA and inflammation on MRI; it does not mean everyone with an erosion needs this medicine. A short steroid course for a selected hand flare is also different from long-term daily steroid treatment. [2, 11, 12]

Ask what symptom the medicine should improve, what monitoring it needs and how the result will be judged. Structural damage and inflammation today are separate questions.

6. Knees and hips: some options overlap, others do not

Rehabilitation and appropriately chosen pain treatment are important options. A steroid injection may be considered for persistent symptoms in selected situations; hip injections should be image-guided. Neither automatically replaces the longer-term plan. [3]

For people with obesity and knee OA, semaglutide research found improvements in weight and knee symptoms. ACR now conditionally supports GLP-1 medicines alongside diet and exercise in that population. This is not proof of cartilage regrowth or of the same joint benefit in everyone with hip or hand pain. [2, 16]

A swollen knee does not automatically require methotrexate. Knee trials have produced different results, and current ACR guidance recommends against its routine use for knee and hip OA. That statement does not address a separate reason to take it, such as another inflammatory disease. [2, 13, 14]

7. Feet, ankles, shoulders and the spine need their own assessment

Feet: a shoe or insert should solve a specific walking or pressure problem. One controlled great-toe study did not find the tested contoured insert better than a sham insert for the main pain outcome. That does not make every shoe change pointless; it makes checking your own result important. [17, 18]

Ankles: the 2026 AAOS guideline advises against hyaluronic acid alone and against routine platelet-rich plasma (PRP). Some other options are based mainly on expert agreement because stronger studies are lacking. An ankle recommendation is not automatically a recommendation for every foot joint. [8]

Shoulders: pain may involve the main shoulder joint, the smaller joint above it or other structures. The guideline for the main shoulder joint does not show benefit from hyaluronic acid and does not treat all shoulder conditions as identical. [9]

Spine: changes on a scan do not automatically establish why you hurt or make a nerve procedure the next step. Guidelines disagree about facet-joint radiofrequency treatment. The explanation of the pain needs to come before choosing that procedure. [19, 20]

8. Why two clinicians may describe the evidence differently

Professional organizations can disagree about the same treatment. For knee PRP, ACR recommends against it, AAOS describes a possible benefit with limited evidence, and VA/DoD says evidence is insufficient to recommend for or against it. These are not three versions of universal approval. [2, 3, 7]

A useful question is: “Which guideline and which study apply to my joint, and what is uncertain?” Also ask which preparation, number of procedures and outcome were actually studied. A clinic’s advertised success rate should not replace that discussion.

The goal is not to collect the most favorable quotation. It is to understand whether the option is reasonable for you and what alternatives remain.

9. “New,” “regenerative” and “approved” are different claims

Improved pain, a changed scan and regrowth of normal cartilage are different outcomes. A study of denosumab in erosive hand OA found a structural signal, but it does not justify changing an osteoporosis injection schedule on your own. [15, 29]

For a paid cell-based, perinatal or exosome treatment, ask for the exact product and regulatory status in your country. FDA warns that such marketed regenerative products are not approved in the United States for orthopedic conditions such as OA. A registered study or registered facility is not the same as approval of the treatment. [22]

Ask about the total cost, follow-up, possible harm and what happens if there is no useful improvement. A hopeful idea can deserve research without already being a proven treatment.

10. Safety questions before adding a medicine

Tell the treating team about prescription medicines, over-the-counter painkillers and supplements. Topical diclofenac is still a nonsteroidal anti-inflammatory drug (NSAID); a gel is not automatically risk-free or safe to combine with another anti-inflammatory medicine. Kidney risk can rise during dehydration or illness. [26, 27]

When low-dose methotrexate is prescribed for a rheumatologic condition, it is taken once weekly, not daily. A dosing-frequency error can be fatal. Confirm written instructions and the monitoring plan rather than copying another person’s regimen. [28]

Do not stop a medicine used for another disease simply because this OA guide does not recommend it for OA. Do not abruptly stop established long-term opioids, or delay/stop denosumab without an appropriate plan. These medicines have separate withdrawal or interruption risks. [29, 30]

11. Before an injection, check the target and the calendar

Confirm which joint and which symptom the procedure is intended to treat. Report recent infection, diabetes, blood-thinning medicines, previous injections and any planned operation. Do not independently stop an anticoagulant. [32]

Hip/knee guidance advises avoiding a steroid injection into the joint within three months before replacement. The operating team should know about an injection request before it is performed. Different procedures may have different requirements; no interval guarantees zero risk. [3]

Afterward, record what improved and for how long. Immediate numbing, later pain relief and improved function are not identical results. A short-lived benefit should lead to a new decision, not an automatic series of repeat injections.

12. When another assessment is the right next step

New persistent swelling in knuckles or wrists may need rheumatology assessment even when previous blood tests were normal. Do not assume that visible finger OA explains every new symptom. [25]

A surgical opinion can be appropriate when a supported joint diagnosis substantially affects life and suitable nonsurgical care is ineffective or unsuitable. NICE advises against automatically excluding referral because of age or body weight; the operation’s individual risks still need assessment. Referral is a discussion, not a commitment to surgery. [4]

For an already appropriate hip/knee replacement candidate who has chosen surgery, there is no universal requirement to buy or try every newer procedure first. Current timing guidance separates unnecessary repetition of treatment from necessary risk preparation. [31]

13. Two examples: a better question can change the decision

“My friend improved after an injection.” That experience is worth hearing, but does not identify your pain source or establish that the same product and schedule will help. Ask which joint, what treatment and what improvement were involved.

“The pain is less, but I still cannot walk to the shop.” Record the remaining limitation. The next task may be adjusting rehabilitation, evaluating another joint, reviewing medicine effects or reconsidering the original explanation—not automatically increasing the same treatment.

These are constructed examples, not diagnoses. Your plan should state the action already agreed, the benefit you hope for and when to review it.

14. My treatment decision sheet

Use this original, unscored sheet to prepare questions and record decisions already made with your treating team. It does not calculate which treatment is best or prescribe a medicine. Keep pain, swelling, function and side effects on separate lines.

My osteoarthritis treatment decision

Olga Goodman, MD · RheumaView · OSTEOARTHRITIS · CHAPTER 11

Your notes stay in this open page only. They are not transmitted or saved after you close or reload it. Print the plan to keep a copy. Record actions already agreed with your treating team; this form does not prescribe treatment. Changing language does not translate your notes.

A personal record, not a diagnostic score or an automatic prescription.

Sources
  1. American College of Rheumatology. 2026 osteoarthritis guideline summary. — 2026.
  2. VA/DoD. Non-Surgical Management of Hip and Knee Osteoarthritis: Provider Summary, version 3. — June 2026.
  3. NICE NG226. Osteoarthritis in over 16s: diagnosis and management—recommendations. — 2022; current page reviewed 2026.
  4. Kloppenburg M et al. 2018 update of the EULAR recommendations for the management of hand osteoarthritis. — 2018 update; 2019 journal issue.
  5. AAOS. Management of Osteoarthritis of the Knee (Non-Arthroplasty), third edition. — August 31, 2021.
  6. AAOS. Management of Ankle Osteoarthritis: evidence-based clinical practice guideline. — Adopted June 4, 2026.
  7. AAOS. Management of Glenohumeral Joint Osteoarthritis. — March 23, 2020.
  8. British Society for Surgery of the Hand BEST guideline: management of thumb-base osteoarthritis. — 2025.
  9. Wang Y et al. Methotrexate to treat hand osteoarthritis with synovitis (METHODS). — 2023.
  10. Kroon FPB et al. Six-week treatment with prednisolone in hand osteoarthritis (HOPE). — 2019.
  11. Kingsbury SR et al. Pain reduction with oral methotrexate in knee osteoarthritis. — 2024.
  12. Zhu Z et al. Low-dose methotrexate for knee osteoarthritis with effusion-synovitis. — 2025.
  13. Wittoek R et al. RANKL blockade for erosive hand osteoarthritis: randomized placebo-controlled phase 2a trial. — 2024.
  14. Bliddal H et al. Once-weekly semaglutide in persons with obesity and knee osteoarthritis (STEP 9). — 2024.
  15. Paterson KL et al. Effect of foot orthoses vs sham insoles in first metatarsophalangeal joint osteoarthritis. — 2022.
  16. AOFAS FootCareMD. Midfoot arthritis. — Current page reviewed September 2026.
  17. BMJ Rapid Recommendation. Commonly used interventional procedures for non-cancer chronic spine pain. — February 2025.
  18. NICE NG59. Low back pain and sciatica in over 16s: assessment and management. — Current guideline page reviewed September 2026.
  19. FDA. Important patient and consumer information about regenerative medicine therapies. — Current page reviewed September 2026.
  20. Ravn C et al. Guideline for management of septic arthritis in native joints (SANJO). — 2023.
  21. NICE NG127. Suspected neurological conditions: recognition and referral—adults. — Current page reviewed September 2026.
  22. NICE NG100. Rheumatoid arthritis in adults: management. — 2018; updated 2020.
  23. MedlinePlus. Diclofenac topical. — Current page reviewed September 2026.
  24. NIDDK. Keeping kidneys safe: smart choices about medicines. — Current page reviewed September 2026.
  25. EMA. New measures to avoid potentially fatal dosing errors with methotrexate for inflammatory diseases. — 2019.
  26. FDA. Boxed warning for severe hypocalcemia with Prolia in advanced chronic kidney disease. — January 19, 2024.
  27. CDC. Clinical Practice Guideline for Prescribing Opioids for Pain—United States, 2022. — 2022.
  28. ACR/AAHKS. Optimal timing of elective hip or knee arthroplasty after ineffective nonoperative therapy. — 2023.
  29. Uson J et al. EULAR recommendations for intra-articular therapies. — 2021.

Educational information from the author’s personal site. This is not a clinic portal, medical advice for an individual, or a way to send a message to your treating team. Private expert services, when offered, are paid directly and are not billed to insurance.

Back to top

Share this page

FacebookLinkedInXWhatsAppTelegram

Topics: osteoarthritis